Elan, Dainippon deal

ELN received exclusive North American marketing rights to Dainippon’s Zonisamide for epilepsy.

Read the full 120 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE